Microbial encapsulation and targeted delivery mechanisms of double emulsion loaded with probioticsa state-of-art review
Metabolic syndrome with elevated liver enzymes : Patients presenting with multiple metabolic risk factors (central obesity, hypertension, dyslipidemia, impaired fasting glucose) and persistently elevated ALT/AST may benefit from the comprehensive metabolic improvements offered by GLP-1 therapy
It remains unapproved for human use as of April 2026
The installed base, clinical familiarity, and proven weight-loss performance still sit primarily in injectionsand the system (specialty prescribing, manufacturing, supply chains) has been built around them
Experimental work on intestinal anastomosis models and related gastrointestinal injury systems has evaluated endpoints including tissue tensile strength, inflammatory signaling markers, and vascularization within healing intestinal segments